First Brands Group debt targeted by Apollo Global Management - report
ANN ARBOR, Mich. -On Tuesday, Esperion Therapeutics (NASDAQ:ESPR), the biopharmaceutical company, reported better-than-expected fourth quarter results and provided an upbeat outlook for 2025.
The company saw its shares jump 9.49% after the release in premarket trading.
The company posted Q4 revenue of $69.1 million, up 114% YoY and surpassing analyst estimates of $63.45 million. U.S. net product revenue grew 52% YoY to $31.6 million, driven by a 45% increase in retail prescription equivalents.
Adjusted loss per share came in at $0.11, narrower than the $0.14 loss analysts were expecting.
For the full year 2024, total revenue soared 186% to $332.3 million, with U.S. net product revenue up 48% to $115.7 million.
"The significant progress we and our partners achieved throughout 2024 has formed a strong foundation that empowers us to enter the new year with a bold vision centered around three strategic pillars for building a blockbuster company: continued revenue growth, operating profitability, and portfolio expansion and pipeline advancement," said Sheldon Koenig, President and CEO of Esperion.
Looking ahead, Esperion expects full year 2025 operating expenses to be in the range of $215 million to $235 million.
The company ended Q4 with $144.8 million in cash and cash equivalents, up from $82.2 million at the end of 2023.
Esperion also announced it has initiated development of two triple combination products in the U.S. with bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.